Research Developments in Psoriasis: AAD 2022

To participate in this activity, please:

Plaque psoriasis is responsible for a substantial burden on patients, their families, and the healthcare system. To address this burden, important treatment advances continue to be made, including a better understanding of the long-term safety and efficacy of approved medications, as well as the introduction of new classes of medications. Join Steven Feldman, MD, PhD, as he reports on research results of these advances presented at the 2022 American Academy of Dermatology Meeting. Three studies presented as posters in the meeting will be described, along with expert comments on the clinical implications of the study results by Dr. Feldman and the principal investigator. 

Course Credit:

0.75 AMA PRA Category 1 CreditsTM


Opens: 2022-05-26
Closes: 2023-05-26

Target Audience:

This activity was developed for dermatologists, dermatology advanced practice providers, and other clinicians who manage patients with moderate to severe plaque psoriasis.

This activity is supported by an educational grant from Janssen Biotech, Inc, administered by Janssen Scientific Affairs, LLC and Arcutis Biotherapeutics, Inc.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Tim Drake, PharmD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Steven R. Feldman, MD, PhD

    Professor of Dermatology, Pathology, and Social Sciences & Health Policy
    Wake Forest University Health Sciences
    Winston-Salem, North Carolina

Learning Objectives

  • Summarize the latest research developments in the treatment of plaque psoriasis
  • Describe how new data and recommendations can impact clinical practices to improve care
  • Incorporate evidence-based research into clinical practice

Faculty Disclosures

Steven R. Feldman, MD, PhD

Consultant:  AbbVie, Accordant, Almirall, Alvotech, Arcutis, Arena, Argenx, Biocon, BMS, Boehringer, Dermavant, Forte, Helsinn, Janssen, Leo, Mylan, Novartis, Pfizer, Samsung, Sanofi, Sun, UCB, vTv, Voluntis        

Research Support:  AbbVie, Almirall, Galderma, Janssen, Lilly, Pfizer, UCB

Speakers Bureau:  AbbVie, Alvotech, Amgen, Janssen, Lilly, Regeneron, Sanofi, Sun

Stockholder: Sensal Health